Probiodrug (PBD-NA): Lifting the veil on Phase IIb design

goetzpartners securities Limited

10-Apr-2018 / 11:41 GMT/BST


Free to access research and investor meetings in a post-MiFID2 world

Probiodrug (PBD-NA): Lifting the veil on Phase IIb design
Recommendation: OUTPERFORM
Target Price: EUR71 (adjusted from EUR91)
Current Price: EUR10.75 (cob on 9th April 2018)

KEY TAKEAWAY

The key updates at Probiodrug’s FY2017 results were the overall strategy for the Phase IIb programme and the detailed design of the European study for lead compound PQ912, a small molecule glutaminyl cyclase (“QC”) inhibitor in development for Alzheimer’s disease (“AD”). The trial design incorporates the draft guidance provided by the FDA and the EMA in February 2018 for the development of drugs in early AD patients, with a focus on detecting changes in cognition thus building on the clinical data from the successful Phase IIa study. The first patient for the slightly more advanced European trial is expected to be enrolled in Q4/2018E, with results possible in Q3/2021E. Strong positive data for both the European and the US trial could lead to accelerated / conditional approval and launch in 2023E. We reiterate our OUTPERFORM recommendation and adjust our target price to EUR71 (from EUR91).

Phase IIb design reflects recent FDA and EMA draft guidance for early AD trials

Past Phase III trial failures in AD have in many cases been due to exploratory trials not providing bona fide proof-of-concept to inform Phase III. In contrast, Probiodrug is making every effort to ensure that this is not the case for its own Phase IIb programme. A key element of the PQ912 Phase IIb development strategy is the focus on cognition and function (activity of daily living) through the assessment of neuropsychological and functional endpoints, respectively, and the assessment of the pathophysiological changes that characterise early AD through the measurement of biomarkers. The types of assessments overlap with those from the successful Phase IIa trial, which in our view increases the chance of trial success.

De-risked European trial includes interim safety analysis

The trial design includes a safety analysis once 90 patients have been treated for 3 months with the 300mg BID dose. The study will only continue and enrol the target population of 250 patients if the tolerability meets pre-specified criteria set out by the data safety monitoring board. This approach reduces the risk of continuing a trial that would ultimately fail due to safety / tolerability issues, in our view.

Valuation based on NPV for PQ912 assumes licensing deal is signed by YE2018

Our new TP of EUR71 per share is based on our risk-adjusted net present value (“rNPV”) for PQ912 in AD plus cash at YE2017 and includes an estimated $25m upfront payment from a biopharma licensing deal in 2018E. We model 2023E sales of $250m and peak global sales in excess of $15bn in 2030E, with Probiodrug entitled to $475m in upfront ($25m), as well as clinical ($50m), regulatory ($275m) and sales-based ($125m) milestone payments, plus royalties on sales at a fixed rate of 12%. We apply a probability of success for PQ912 to reach the market of 25%.

Kind regards,

Brigitte de Lima, PhD, CFA | Analyst
goetzpartners Healthcare Research Team | Research Team

goetzpartners securities Limited

The Stanley Building, 7 Pancras Square, London, N1C 4AG, England, UK.

T +44 (0) 203 859 7725 | healthcareresearch@goetzpartners.com / brigitte.delima@goetzpartners.com

www.goetzpartnerssecurities.com

Registered in England No. 04684144.

Managing Directors: Dr Stephan Goetz, Martin Brunninger and Ulrich Kinzel.

GPSL publishes and distributes “Investment” Research and “Corporate Sponsored” Research. Our Corporate Sponsored Research and investor meetings are free to access / attend and are not classified as an inducement in a post-MiFID2 world. GPSL does not offer any execution or market making services.

To be added, or to change your subscriptions or be removed / unsubscribed entirely from our CRM, please e-mail: ResearchProduction@goetzpartners.com

About GPSL: goetzpartners securities Limited is a member of the goetzpartners group and a leading true pan European investment bank and research firm. We bring together a wide range of expertise, insights and innovations to advance the interests of our clients around the world. The fast-changing environment brings challenges for businesses and investors. Research innovation, digital transformation and disruptive business ideas reshuffle the corporate world in a yet unexperienced pace. Our sector knowledge and our global footprint bring together deep understanding of the industry, corporate intelligence and a wide network of top decision makers.

This research report is intended for use only by persons who qualify as professional investors or eligible counterparties (institutional investors) in the applicable jurisdiction, and not by any private individuals or other persons who qualify as retail clients.

This e-mail (including any attachments) from goetzpartners securities Limited (“GPSL”) is confidential and may contain information which is proprietary, privileged or otherwise legally protected against unauthorised use or disclosure. If you receive this e-mail in error or are not the intended recipient of this e-mail, please delete and destroy all copies in your possession, notify the sender that you have received this e-mail, and note that any review or dissemination of, or the taking of any action in reliance on this e-mail is expressly prohibited. GPSL shall not be liable for the improper or incomplete transmission of the information contained in this e-mail nor for any delay in its receipt or damage to your system. GPSL does not guarantee that the integrity of this e-mail has been maintained nor that this e-mail is free of viruses, interceptions or interference and makes no warranties in relation to these matters. This is not an offer or a solicitation to buy or sell securities or investment products, or an official confirmation. GPSL record electronic and phone communications in accordance with FCA and MiFID2 regulations, they will be monitored for regulatory and training purposes. GPSL is authorised and regulated by the Financial Conduct Authority of the United Kingdom (Firm Reference Number: 225563).

GPSL Equity Research publications are available on the following aggregators and via news distribution circuits (For Institutional Use Only): AlphaSense, Bloomberg (GOET), Capital IQ, EQS, FACTSET, RNS Reach and Thomson Reuters.

If you cannot click on the above hyperlink please copy the below link and paste it into your browser for the full pdf version of the equity research report:

https://gp.bluematrix.com/sellside/EmailDocViewer?encrypt=6d5fd2cf-3d04-4f2b-a0b6-41e5b47a53ed&mime=pdf&co=gp&id=paul.dunne@goetzpartners.com&source=libraryView


Dissemination of a CORPORATE NEWS, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.


End of Announcement – EQS News Service

show this